- Home
- QTTB vs GGR Comparison
QTTB vs GGR Comparison
Compare QTTB & GGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QTTB | GGR |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Taiwan |
| Employees | N/A | 1416 |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.0M | 82.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | QTTB | GGR |
|---|---|---|
| Price | $5.56 | $4.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 306.7K | 7.3K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $53,737,000.00 | N/A |
| Revenue This Year | N/A | $5.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $0.24 |
| 52 Week High | $8.05 | $6.21 |
Technical Indicators
Market Signals| Indicator | QTTB | GGR |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 63.55 |
| Support Level | $5.51 | $3.63 |
| Resistance Level | $7.69 | $4.31 |
| Average True Range (ATR) | 0.64 | 0.23 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 32.93 | 66.88 |
Price Performance
Historical ComparisonAbout QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.